Are you attending the 2nd Annual Psychedelic Therapeutics and Drug Development Conference in Washington, DC on May 23-24, 2022? Apex Innovative Sciences’ esteemed Vice President of Scientific Affairs and Clinical Development, Brett A. English, Pharm.D., Ph.D., will be in attendance and available to meet!
Apex is actively involved in supporting the clinical development of psychedelics and is currently conducting a trial evaluating psilocybin for the treatment of Major Depressive Disorder. Reid Robison, MD, MBA, a member of Apex’s Scientific Advisory Board, was recently published in the Psychiatric Times (Volume 39, Issue 2), authoring an article entitled “Psychedelics and the Future of Psychiatry” on how psychedelic drugs are gaining mainstream acceptance as safe and well-tolerated medicines.
To learn more about how Apex can support your psychedelic clinical trials, please visit: https://www.apexsci.com/psychedelics-research/